Cell replacement for Parkinson's disease:advances and challenges  

作　　者：Bin Xiao Eng-King Tan 

机构地区：[1]Department of Neurology,National Neuroscience Institute,Singapore [2]Neuroscience and Behavioral Disorders Program,Duke-NUS Medical School,Singapore

出　　处：《Neural Regeneration Research》2023年第12期2693-2694,共2页中国神经再生研究（英文版）

基　　金：the Singapore Ministry of Health's National Medical Research Council (Open Fund Large Collaborative Grant (MOH-000207);Singapore Translational Research (STaR) Investigator A word (NMRC/STaR/0030/2018) to EKT,CS-IRG-NIG,OF-YIRG and TA award to BX) for their support。

摘　　要：Parkinson's disease(PD), characterized by the loss of dopaminergic(DA) neurons in the substantia nigra pars compacta(SNpc) of the midbrain, is a prototype neurological disease that is suitable for cellular replacement therapy. Levodopa has been utilized to replace the insufficient dopamine released by degenerating DA neurons since the 1960s and it remains the cornerstone of PD treatment. However, as the disease progresses.

关 键 词：DOPAMINE CORNERS replace 

分 类 号：R742.5[医药卫生—神经病学与精神病学]